HIV positivity and anal cancer outcomes: A single-center experience

详细信息    查看全文

• 作者：Nicole Wieghard ; M.D.^a ; Kyle D. Hart ; M.S.^a ; Katherine Kelley ; M.D.^a ; Kim C. Lu ; M.D.^a ; Daniel O. Herzig ; M.D.^a ; Timur Mitin ; M.D. ; Ph.D.^b ; Charles R. Thomas Jr. ; M.D.^b ; Vassiliki Liana Tsikitis ; M.D.^a ; ^{tsikitis@ohsu.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Anal squamous cell carcinoma ; HIV ; Outcomes
• 刊名：The American Journal of Surgery
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：211
• 期：5
• 页码：886-893
• 全文大小：484 K

文摘

Anal cancer remains common among human immunodeficiency virus (HIV) patients. Chemoradiation has had mixed results. We evaluated outcome differences by HIV status.

Methods

We retrospectively analyzed 14 HIV+ and 72 HIV− anal cancer patients (2000 to 2013). Outcomes included chemoradiation tolerance, recurrence, and survival.

Results

HIV+ patients were more often male (100% vs 38%, P < .001) but diagnosed at similar stages (P = .49). They were less likely to receive traditional chemotherapy (36% vs 86%, P < .001). Recurrence (P = .55) and survival time (P = .48) were similar across groups. HIV+ patients had similar colostomy-free survival (P = .053). Receipt of 5-fluorouracil/mitomycin C (MMC) chemotherapy predicted recurrence-free and overall survival (Hazard ratios .278, .32). HIV status did not worsen recurrence (P = .71) or survival (P = .57).

Conclusions

HIV+ patients received more non-MMC–based chemoradiation but had equivalent colostomy-free, recurrence, and overall survival. Use of 5-fluorouracil/MMC chemotherapy increased after 2008.